Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | NPR1 | P16066 | 7/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.41 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4358026 | 0.89 | ERN1 (0.53) | MAP4K4ERN1EGLN1NPR1PDE5A | |
| SCHEMBL4353458 | 0.86 | CCNE2 (0.48) | MAP4K4EGLN1NPR1PDE5AACP1 | |
| SCHEMBL4355955 | 0.85 | MAP4K4 (0.53) | MAP4K4LIMK1ERN1MEN1KMT2A | |
| SCHEMBL4358307 | 0.82 | CYP1A2 (0.52) | EGLN1NPR1PDE5AACP1FYN | |
| SCHEMBL4352004 | 0.82 | ALOX15 (0.51) | EGLN1NPR1PDE5AACP1 | |
| SCHEMBL4363790 | 0.82 | HPGD (0.43) | EGLN1NPR1PDE5AACP1 | |
| SCHEMBL4353939 | 0.81 | NPR1 (0.46) | EGLN1NPR1PDE5AACP1 | |
| SCHEMBL4354827 | 0.81 | EGLN1 (0.52) | EGLN1NPR1PDE5AACP1 | |
| SCHEMBL4353710 | 0.81 | EGLN1 (0.52) | EGLN1NPR1PDE5AACP1 | |
| SCHEMBL4349640 | 0.81 | MAP4K4 (0.46) | MAP4K4EGLN1NPR1PDE5AACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | claimed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | claimed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | claimed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | claimed |
| WO-2008009078-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2008009078-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | MAP4K4 1801/4885LIMK1 3999/4885ERN1 3389/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | MAP4K4 1801/4885LIMK1 3999/4885ERN1 3389/4885 |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR5A2, NR4A1 | MAP4K4 1921/4885LIMK1 4407/4885ERN1 3469/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | MAP4K4 1837/4885LIMK1 4512/4885ERN1 3401/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | MAP4K4 1837/4885LIMK1 4512/4885ERN1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.